You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 1, 2024

CLINICAL TRIALS PROFILE FOR PERMAX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PERMAX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00260793 ↗ Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease Unknown status Colorado Neurology Phase 3 2005-11-01 The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level.
NCT00260793 ↗ Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease Unknown status GlaxoSmithKline Phase 3 2005-11-01 The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level.
NCT00260793 ↗ Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease Unknown status Agarwal, Pinky, M.D. Phase 3 2005-11-01 The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PERMAX

Condition Name

Condition Name for PERMAX
Intervention Trials
Parkinson's Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PERMAX
Intervention Trials
Parkinson Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PERMAX

Trials by Country

Trials by Country for PERMAX
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PERMAX
Location Trials
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PERMAX

Clinical Trial Phase

Clinical Trial Phase for PERMAX
Clinical Trial Phase Trials
Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PERMAX
Clinical Trial Phase Trials
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PERMAX

Sponsor Name

Sponsor Name for PERMAX
Sponsor Trials
Colorado Neurology 1
GlaxoSmithKline 1
Agarwal, Pinky, M.D. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PERMAX
Sponsor Trials
Other 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.